PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 78 filers reported holding PROGENICS PHARMACEUTICALS IN in Q3 2014. The put-call ratio across all filers is 0.91 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $351,000 | -83.7% | 59,000 | -79.9% | 0.00% | -82.4% |
| Q3 2017 | $2,159,000 | -25.0% | 293,400 | -30.8% | 0.02% | -32.0% |
| Q2 2017 | $2,877,000 | +190.0% | 423,700 | +86.2% | 0.02% | +150.0% |
| Q1 2016 | $992,000 | -82.0% | 227,600 | -74.6% | 0.01% | -83.1% |
| Q4 2015 | $5,500,000 | +58.5% | 897,170 | +47.8% | 0.06% | +47.5% |
| Q3 2015 | $3,471,000 | +3.4% | 606,871 | +34.9% | 0.04% | +2.6% |
| Q2 2015 | $3,357,000 | +136.2% | 450,029 | +89.4% | 0.04% | +129.4% |
| Q1 2015 | $1,421,000 | +621.3% | 237,600 | +813.8% | 0.02% | +466.7% |
| Q4 2014 | $197,000 | +61.5% | 26,000 | +10.6% | 0.00% | +50.0% |
| Q3 2014 | $122,000 | -19.2% | 23,500 | -32.9% | 0.00% | 0.0% |
| Q2 2014 | $151,000 | -91.2% | 35,000 | -91.6% | 0.00% | -93.1% |
| Q1 2014 | $1,712,000 | – | 418,485 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARDSLEY ADVISORY PARTNERS LP | 1,255,000 | $5,823,000 | 1.12% |
| Phocas Financial Corp. | 1,146,292 | $5,319,000 | 0.54% |
| Worth Venture Partners, LLC | 138,357 | $641,000 | 0.36% |
| RICE HALL JAMES & ASSOCIATES, LLC | 2,293,179 | $10,640,000 | 0.34% |
| Monashee Investment Management LLC | 240,000 | $1,114,000 | 0.26% |
| BKS ADVISORS, LLC | 118,587 | $550,000 | 0.22% |
| PINNACLE ASSOCIATES LTD | 1,418,391 | $6,581,000 | 0.15% |
| FARALLON CAPITAL MANAGEMENT LLC | 4,200,820 | $19,492,000 | 0.15% |
| Fosun International Ltd | 472,580 | $2,174,000 | 0.14% |
| CARILLON TOWER ADVISERS, INC. | 3,948,024 | $18,318,000 | 0.13% |